Navigation Links
ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
Date:10/27/2011

ddress until November 18, 2011.

About ViroPharma Incorporated ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, Friedreich's Ataxia (FA), adrenal insufficiency and C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE) and CDI; for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2011, our ability to successfully commercialize Cinryze and Buccolam in the EU, our ability to complete manufa
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
2. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
3. ViroPharma Announces Additional Securities Repurchase Program
4. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
5. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
6. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
7. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
8. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
9. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
10. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
11. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Some 2,500 scientists and ... in Montreal for the largest ... a discipline that draws researchers from fields as far ... as diverse as designing new manufacturing processes to creating ... special time because the United Nations has declared 2014 ...
(Date:7/28/2014)...  VigeneTech, Inc, in collaboration with BioLegend, Inc., ... Software, an OEM software solution for analysis of ... offers varieties of bead-based multi-analyte immunoassay products for ... VigeneTech,s data analysis software, FCS data files can ... LEGENDplex™ software is a robust ...
(Date:7/28/2014)... New Zealand , July 28, 2014 /PRNewswire/ ... in Sweden has validated ... multiple vendor platforms and has associated volumetrically assessed ... in Cancer Epidemiology, Biomarkers & Prevention ... mammographic density: a tool for widespread breast cancer ...
Breaking Medicine Technology:All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 2All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 3All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 4All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 5All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 6VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4
... , DENVER , Jan. 28 Global ... Board: GLOB), an international healthcare information technology company, today announced ... management software and Donor Doc® health history questionnaire to Community ... Kansas City, Missouri . Terms of the agreement were ...
... , , MOUNTAIN VIEW, Calif. ... announced the initiation of a Phase I clinical trial ... autoimmune diseases.  CCX168 is a highly potent and very ... a component of the body,s complement system and a ...
Cached Medicine Technology:Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 2Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 3Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 4Global Med Technologies(R)' Solution of Choice for Important Regional Blood Center 5ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... heart rhythm irregularities are more likely to get a pacemaker ... fact, the study of more than 16,000 people found that ... to get a pacemaker than those without the memory-robbing condition. ... folks with dementia are so much more likely to be ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 SIMpalm ... for iOS, App is available on iTunes for download ... its kind, Audio Chef allows you to listen and cook ... the easy way: simply get out the ingredients and equipment, ... to measure or prepare ingredients ahead of time, just relax ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The Oakwood ... Harris, Birkhill, Wang, Songe and Associates, PC that will ... countless tomorrows to come. , The HBWS group ... for more than $2.5 million in donations. Through their ... sponsors for the Oakwood Women’s Healthcare Classic for the ...
(Date:7/28/2014)... JOLLAWhen you,re expecting somethinglike the meal you,ve ordered ... unique electrical rhythms sweep through your brain. ... they reflect a symphony of cellsboth excitatory and ... role has been debated, gamma waves have been ... the patterns have been tied to schizophrenia, Alzheimer,s ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, ... sleep apnea in children, but a new study confirms that ... they,re already overweight. The researchers said that,s a concern, ... health problems -- including, ironically, sleep apnea. But they,re not ... they said, doctors and parents should be aware that a ...
Breaking Medicine News(10 mins):Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3
... contraceptive Lybrel, which is designed to eliminate monthly menstrual ... contains a lower dose of synthetic hormones in a ... days a year with no placebo pills. The usual ... consecutively, followed by seven placebo pills. ,According ...
... Jefferson Medical College have used gene therapy to reverse ... this gene therapy strategy had "unique and additive ... beta-blockers. ,Reporting in the American Heart Association ... director of the Center for Translational Medicine and the ...
... Researchers at the University of Warwick have found that sexual ... tasks such as navigating with a map in a ... of sexual orientation and withers all mens minds alike just ... worked with the BBC to collect data from over 198,000 ...
... a Californian firm has claimed to have developed super-oxidised ... ,The water, which is made by passing it ... kills bacteria, virus and fungi. ,The company ... aureus (MRSA). ,We would welcome any safe ...
... pregnancy may be exposing their baby to the risk ... study published in the journal Biological sychiatry. ... the mothers womb puts genetically susceptible children at an ... course of study, the researchers studied male and female ...
... called FGFR2 could accelerate the development of new treatments ... at Washington University School of Medicine in St. ... Trust Sanger Institute, which is part of Cambridge University; ... findings in the May 21, 2007, online version of ...
Cached Medicine News:Health News:FDA Approves Wyeth's Oral Contraceptive Lybrel 2Health News:Scientists Use Gene Therapy to Reverse Heart Failure in Animals 2Health News:Scientists Use Gene Therapy to Reverse Heart Failure in Animals 3Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 2Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 3
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
... designed specifically for posteror segment surgical procedures. ... fluid. A high pressure luer lock tubing ... 8in (20cm) long. ID - .02in (.50mm); ... with standing injections of viscoelastic fluids. 30G ...
Product designed specifically for posteror segment surgical procedures. Facilitates posterior segment infusion. Flexible tubing 10in (25cm)....
For surgical treatment, repair and irrigation of the nasolacrimal system. Stainless steel probes, 20G x 1 3/4in (.90 x 45cm) Silicone rod, length 13 3/4in (40cm), Diameter.032in (.80mm)...
Medicine Products: